Anemia In Chronic Kidney Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Anemia In Chronic Kidney Disease Market Outlook
Thelansis’s “Anemia In Chronic Kidney
Disease Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Anemia In Chronic Kidney Disease
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Anemia In Chronic Kidney Disease
Overview
Anemia in
Chronic Kidney Disease (CKD) is a prevalent condition, particularly in advanced
stages, with a frequency exceeding 50% in patients at stages 4 and 5, and often
manifests earlier in individuals with diabetes mellitus (DM). It is
characterized as normocytic normochromic, hyperproliferative anemia,
contributing significantly to poor outcomes and increased mortality in CKD. The
primary cause is the diminished renal production of erythropoietin (EPO), the
hormone vital for red blood cell production. Patients with CKD experience
elevated iron losses attributed to uremia-associated platelet dysfunction,
frequent phlebotomy, and blood entrapment during dialysis, resulting in annual
iron losses estimated at 1–3 g in hemodialysis patients. Diagnostic tests for
CKD-related anemia include complete blood count (CBC) with differential,
peripheral smear, iron indices (iron, ferritin, total iron binding capacity,
transferrin saturation), as well as assessments of iron, vitamin B, and folate
levels to exclude other reversible causes. Thyroid function tests are also
conducted to rule out alternate etiologies.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment